Open house discount agreements Adalimumab (ATC L04AB04)
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Adalimumab, ATC L04AB04
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum amount is provided. The actual business volume is unknown.
The open-house contract can be automatically suspended if AOK Bayern enters into a national or regional discount agreem...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Provision of pharmaceutical product Adalimumab (ATC L04AB04) under a discount agreement with AOK Bayern.
- Non-exclusive, open-house model where all eligible pharmaceutical companies can participate.
Show full summary
This is an open-house model (not a classic procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Adalimumab (ATC L04AB04). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and the contract. The agreement runs from September 1, 2025, to August 31, 2027, with the possibility to join at any time until July 3, 2027. No estimated value is provided.
Risks
No estimated value or framework maximum amount is provided. The actual business volume is unknown.
The open-house contract can be automatically suspended if AOK Bayern enters into a national or regional discount agreem...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company.
Administrative
- Submit a signed declaration of reliability.
- Submit the signed contract and annex listing the covered medicines.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house discount agreements Adalimumab (ATC L04AB04)
Non-exclusive discount agreement for Adalimumab (ATC L04AB04) with a duration from 01.09.2025 to 31.08.2027. All eligible pharmaceutical companies can join. The contract is identical for all participants.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Adalimumab, ATC L04AB04
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 458658-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum amount is provided. The actual business volume is unknown.
The open-house contract can be automatically suspended if AOK Bayern enters into a national or regional discount agreem...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications